TMCnet News

Acute Lung Injury Pipeline Review, H1 2016 - 14 Companies & Approx 42 Molecules - Research and Markets
[July 21, 2016]

Acute Lung Injury Pipeline Review, H1 2016 - 14 Companies & Approx 42 Molecules - Research and Markets


Research and Markets has announced the addition of the "Acute Lung Injury - Pipeline Review, H1 2016" report to their offering.

According to 'Acute Lung Injury - Pipeline Review, H1 2016'; Acute Lung Injury pipeline therapeutics constitutes close to 42 molecules, out of which approximately 32 molecules are developed by Companies and the remaining by Universities/Institutes.

Furthermore, the publisher says; Acute Lung Injury Acute lung injury (ALI) is a common condition that is characterized by acute severe hypoxia that is not due to left atrial hypertension. ALI is most often seen as part of a systemic inflammatory process, particularly systemic sepsis, where the lung manifestations parallel those of other tissues. Causes of ALI include sepsis, burns, radiation, inhalation of noxious fumes, and fat embolism. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness.

The report 'Acute Lung Injury - Pipeline Review, H1 2016' oulays comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies / Universities.



It also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. Currently, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 22 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively.

Companies Mentioned


  • Altor BioScience Corporation
  • Apeptico Forschung und Entwicklung GmbH
  • Commence Bio, Inc.
  • CompleGen, Inc.
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Quark Pharmaceuticals, Inc.
  • S-Evans Biosciences, Inc.
  • Silence Therapeutics Plc
  • Stemedica Cell Technologies, Inc.
  • Windtree Therapeutics, Inc.

For more information visit http://www.researchandmarkets.com/research/fbghgt/acute_lung_injury

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To TMCnet.com's Homepage ]